<reuters><date> 4-MAR-1987 17:07:06.01</date><topics /><title>HUNTERDON &lt;HUNT&gt; SETS DENTAL VENTURE</title><body>Hunterdon Pharmaceuticals Inc
said it formed a joint venture with &lt;Chesapeake Biological
Laboratories&gt; and &lt;E.B. Michaels Research Associates&gt; to
develop C31G, a substance that may be useful in the treatment
or prevention of plaque.
    The substance, tested in pre-clinical trials at the
University of Pennsylvania, also has other uses as an
anti-fungal or anti-bacterial agent, the company said.
    It said Chesapeake Biological, a private company, owns 55
pct of the venture, E.B. Michaels 10 pct, while it holds the
remaining interest, and the patent for C31G.
 Reuter
</body></reuters>